Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 16: | Line 16: | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | + | ||
[[Category:ALK inhibitors]] | [[Category:ALK inhibitors]] | ||
[[Category:AXL inhibitors]] | [[Category:AXL inhibitors]] | ||
Revision as of 23:15, 28 February 2020
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Also known as
- Code name: ASP2215
- Brand name: Xospata